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Background: Infused particles induce thrombogenesis, impair microcirculation and modulate immune response.
We have previously shown in critically ill children, that particle-retentive in-line filtration reduced the overall
complication rate of severe events, length of stay and duration of mechanical ventilation. We now evaluated the
influence of in-line filtration on different organ function and thereby elucidated the potential underlying
pathophysiological effects of particle infusion.
Methods: In this single-centre, prospective, randomized controlled trial 807 critically ill children were assigned to
either control (n = 406) or filter group (n = 401), the latter receiving in-line filtration for complete infusion therapy.
Both groups were compared regarding the differences of incidence rates and its 95% confidence interval (CI) of
different organ dysfunction as defined by the International Pediatric Sepsis Consensus Conference 2005.
Results: The incidence rates of respiratory (−5.06%; 95% CI, −9.52 to −0.59%), renal (−3.87%; 95% CI, −7.58 to
−0.15%) and hematologic (−3.89%; 95% CI, −7.26 to −0.51%) dysfunction were decreased in the filter group. No
difference was demonstrated for the occurrence rates of cardiovascular, hepatic, or neurologic dysfunction between
both groups.
Conclusions: In-line filtration has beneficial effects on the preservation of hematologic, renal and respiratory
function in critically ill patients. The presented clinical data further support our hypothesis regarding potential
harmful effects of particles. In critically ill patients infused particles may lead to further deterioration of the
microcirculation, induce a systemic hypercoagulability and inflammation with consecutive negative effects on organ
function.
Trial registration: ClinicalTrials.gov number; NCT00209768
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Infusion of particles is a side effect of intravenous ther-
apy [1-3]. Particulate contamination is inherent to the
applied drug formulation. It arises from drug incompati-
bility reactions, incomplete reconstitution of drugs, or
components of the infusion systems [4]. On an intensive
care unit, up to one million particles may be infused per
day [3] depending on the complexity and quantity of the
infused solutions [5]. Different mechanisms of particle* Correspondence: Jack.Thomas@mh-hannover.de
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reproduction in any medium, provided the ordamage to various organs have been proven either by ex-
perimental or clinical studies. These include mechanical
blockage of small–diameter arterioles and capillaries
[6], activation of platelets, neutrophiles and/or endo-
thelial cells [1] with a subsequent generation of occlu-
sive micro-thrombi [7], and granuloma formation via
foreign-body giant cell production [7,8]. Particles modu-
late the immune response [5] and lead to a deterioration
of the microcirculation by loss of functional capillary
density [6].
In-line filters have been shown to almost completely
prevent particles from being infused [9,10] and are ablel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bacteria and fungal spores [11]. First reports on the clin-
ical relevance of infused particles have been published in
1960 [12,13]. Ever since, their pathogenetic effect on
critically ill patients as well as the clinical value of par-
ticle retentive in-line filtration have been a matter of on-
going discussion [8]. Recently, several clinical studies
revealed new insights in in-line filtration and its benefit
for critically ill patients. In a single center trial involving
88 neonates van Lingen et al. found a significant reduc-
tion in the incidence of typical neonatal complications
by the use of 0.2 μm in-line filters [14]. Consistent with
these findings, we demonstrated a significant benefit of
in-line filtration in a prospective, randomized, controlled
trial including more than 800 critically ill children.
In-line filtration was effective in reducing the overall
complication rate of severe events such as systemic in-
flammatory response syndrome (SIRS), sepsis, thrombosis,
and organ failure. Length of stay (LOS) and duration of
mechanical ventilation on a pediatric intensive care unit
(PICU) were also shortened when in-line filtration was
used [15].
In the current study we further analyzed the influence
of in-line filtration on organ dysfunction which had not
been investigated in the first analysis (ClinicalTrials.gov
number; NCT00209768). The organ dysfunction crite-
ria were developed by the International Pediatric Sepsis
Consensus Conference 2005 [16] to asses changes or de-
terioration of organ function. Additionally to the prima-
ry and secondary endpoints, in cases where criteria for
organ dysfunctions were met, this has been prospectively
documented for each patient.
The purpose of this study was to further elucidate the
clinical impact of in-line filtration on the different organ
systems and thereby give further insights into potential
pathophysiological effects of particle infusion.
Methods
Study design
This single-centre, prospective, randomized, controlled
trial was conducted in an interdisciplinary PICU of a
university hospital. The ethical committee of Hannover
Medical School approved the study protocol. Sponsor-
ship was provided by a research grant of Hannover Me-
dical School. Additional funding was supplied by an
unrestricted grant from Pall, Dreieich, Germany and B.
Braun Melsungen, Germany. Both companies supplied in-
line filters.
Patient enrolment and randomization
In total, 2542 patients below the age of 18 years admit-
ted to PICU were initially assessed for eligibility. Ex-
pected death within 48 hours of admission, recruitment
for other trials and absence of any intravenous therapyled to an exclusion from the study (n = 88). Written in-
formed consent was obtained for each child from their
legal guardians on admission. In 38 subjects an informed
consent was not available due to foreign language or
ethical reasons. In 36 patients the guardians refused to
participate in the study and in 1233 cases the guardians
were not available at the time of admission to obtain the
informed consent for participating in the study. Finally,
1147 children were randomized based on a computer gen-
erated simple unrestricted randomization list. These pa-
tients were randomly allocated to either control (n = 565)
or filter (n = 582) group. Length of stay shorter than
6 hours on PICU was predefined as exclusion criterion.
313 children (n = 150 of the control, n = 163 of the filter
group) were discharged from PICU within 6 hours and for
that reason excluded. 8 children allocated to the filter
group and one patient allocated to the control group did
not receive the intended intervention and in 4 patients of
the filter group the intervention was discontinued. 14
patients (n = 8 of the control, n = 6 of the filter group)
were excluded during final validation due to missing of
relevant clinical data in their charts. In total, 807 patients
(406 control, 401 filter group) were included in the final
analysis.
In-line filtration
Infusion regimen was standardized for all patients in
both groups before launching the study. All solutions
and medications were prepared according to manufac-
turer’s instructions. Certain drugs (special antibiotics,
antiviral drugs, antimycotics, chemotherapy) and paren-
teral nutrition were supplied by a centralized intrave-
nous additive service to guarantee chemical stability and
aseptic standards. Before the study a computer based pro-
gram for the analysis and prevention of possible drug in-
compatibilities (KiK 3.0; oData, Rastede, Germany) was
used to optimize the infusion regimen [4]. This optimized
infusion regimen was used for filter and control group.
The filter group received in-line filtration throughout
infusion therapy. In this group all medications and fluids
except blood, plasma proteins or fresh frozen plasma
were administered via an in-line filter. 0.2 μm pore
size positively charged filters (ELD96LLCE/ NOE96E;
Pall, Dreieich, Germany) were used for aqueous solu-
tions and 1.2 μm pore size filters (Intrapur Lipid/ Intrapur
Neonat Lipid; B Braun, Melsungen, Germany) for infusion
of lipid-containing admixtures. In-line filters were arran-
ged in each lumen of a central and peripheral venous
catheter and were replaced after 24 hours (Intrapur
Lipid/Intrapur Neonat Lipid) or 72 hours (ELD96LLCE/
NOE96E) of regular use or in case of blockage. In both
groups, administration sets for lipid-containing admix-
tures were changed every 24 hours, others every 72 hours
as recommended by the Robert Koch Institute [17]. Both,
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the study to ensure correct and safe in-line filter handling.
An open label study design characterized by visible in-line
filters was necessary to ensure maximum safety in drug
administration and to allow nurses to monitor the in-line
filters for imminent blockage.
Data collection
On admission, the paediatric index of mortality (PIM) II
[18], demographic and clinical data were documented in
databases for each patient. Blood chemical studies and
hematologic tests were routinely performed at the time
of admission, daily and when clinically required. Relevant
clinical data were registered for each patient at least every
hour. Several clinically endpoints including sepsis, SIRS,
organ dysfunction etc. were prospectively documented in
the database. The databases were thoroughly checked for
consistency. Any queries were resolved and the final data-
base entries were verified by investigators blinded for the
allocation of the patients.
Endpoints
The details of the primary and secondary endpoints
(ClinicalTrials.gov number; NCT00209768) have been
published previously [15]. Given the low mortality in the
PICU, we chose reduction in the overall complication
rate of major events as the primary endpoint. The study
was designed using a chi-square test for equal propor-
tions and with 80% power to detect a reduction of 10%
in the complication rate for the filter group. Major events
included the incidence of SIRS, sepsis, thrombosis, acute
liver failure, ARDS, acute renal and circulatory failure.
The occurrence of at least one of the preceding events
during the PICU stay accounted for one complication per
patient in the calculation of the overall complication rate.
Complications prior to PICU stay and on admission were
not taken into account.
In this investigation the occurrence of cardiovascular,
respiratory, neurologic, hematologic, renal and hepatic
dysfunction according to International Pediatric Sepsis
Consensus Conference 2005 [16] (for detailed definition
see Table 1) were analyzed in both, filter and control
group during PICU stay. Organ dysfunction on admission
or prior to PICU stay were not taken into account.
Statistical analysis
Concisely, the trial was performed on an intention-to-
treat basis to detect a reduction from 40 to 30% in the
complication rate of major events for the filter group as
the primary endpoint [15]. Major events included the in-
cidence of SIRS, sepsis, thrombosis, acute liver failure,
ARDS, acute renal and circulatory failure. Size and po-
wer of the study were not calculated for detection of a
single reduction in organ dysfunction.Baseline characteristics of the control and filter groups
were compared using the t-test for equality of means.
Differences between the two groups regarding the inci-
dence rates and its 95% confidence interval (CI) (by the
Wald method) were calculated for each organ dysfunction.
Statistical analysis was performed using the Predictive




807 children, allocated to either control (n = 406) or fil-
ter group (n = 401), were included in the final analysis.
As previously shown [15], there were no significant dif-
ferences between both groups regarding baseline demo-
graphic characteristics, underlying disease categories, or
Pediatric Index of Mortality II score (see Table 2).
Organ dysfunction
Patients receiving in-line filtration developed less fre-
quently respiratory dysfunction (9.5% [n = 38] vs. 14.5%
[n = 59]; difference in incidence rates = −5.06%; 95% CI,
−9.52 to −0.59%; filter vs. control group), (Figure 1 and
Table 3). Only 6.0% [n = 24] of the patients assigned to
the filter group developed renal dysfunction, whereas
9.9% [n = 40] of the children of the control group suf-
fered from renal dysfunction (difference in incidence
rates = −3.87%; 95% CI, −7.58 to −0.15%; filter vs. con-
trol group). Moreover, in-line filtration reduced the inci-
dence rate of hematologic dysfunction (4.5% [n = 18]
vs. 8.4% [n = 34]; difference in incidence rates = −3.89%;
95% CI, −7.26 to −0.51%; filter vs. control group). No rele-
vant differences were demonstrated for the incidence rates
of cardiovascular (vs. 13.5% [n = 54] vs. 14.8% [n = 60]; dif-
ference in incidence rates = −1.31%; 95% CI, −6.12 to
3.49%), filter vs. control group), hepatic (5.0% [n = 20]
vs. 6.4% [n = 26]; difference in incidence rates = −1.42%;
95% CI, −4.61 to 1.78%; filter vs. control group), and
neurologic dysfunction (0.7% [n = 3] vs. 0.5% [n = 2]; dif-
ference in incidence rates = 0.26%; 95% CI, −0.83 to 1.34%;
filter vs. control group) between both groups.
Discussion
As previously shown, in-line filtration was highly effect-
ive in reducing the overall complication rate of severe
events (SIRS, sepsis, circulatory failure, acute respiratory
distress syndrome (ARDS), thrombosis, acute renal and
liver failure). Length of stay and duration of mechanical
ventilation on the PICU were also significantly shortened
if in-line filtration was applied [15]. In this additional in-
vestigation, the 95% CIs of the differences in the inci-
dence rates of several organ dysfunction lay on either
side below zero, indicating a statistically significant dif-
ference between both groups (Figure 1). The negative
Table 1 Criteria for organ dysfunction
Cardiovascular Despite intravenous application of >40 ml/kg isotonic volume in 1 hour persisting:
• Decrease in BP (hypotension) <5th percentile for age or systolic BP < 2 SD below normal for age
OR
• Need for vasocative drugs to maintain BP in normal range (use of dopamine in dose >5 μg/kg/min or epinephrine,
norepinephrine, or dobutamine at any dose)
OR
• Two of the following
- Metabolic acidosis (base deficit >5 mmol/l)
- Arterial lactate >2 times upper limit of normal
- Oliguria: urine output <0.5 ml/kg/h
- Prolonged capillary refill >5 sec.
- Core to peripheral body temperature difference >3°C
Respiratory • Oxygenation index <300 in absence of cyanotic heart disease or preexisting lung disease
OR
• PaCO2 >65 mmHg or increase of >20 mmHg over baseline
OR
• Proven need or FiO2 >0.5 in order to maintain saturation ≥92%
OR
• Need for nonelective mechanical ventilation (invasive or non-invasive)
Neurologic • Glasgow Coma Scale (GCS) ≤11
OR
• Acute change in mental status with decrease in GCS ≥3 points from abnormal baseline
Hematologic • Platelet count < 80.000/mm3 or decline of 50% in platelet count from highest value recorded over the past 3 days
(for chronic hematology/oncology patients)
OR
International Normalized Ratio >2
Renal Serum creatinine≥ 2 times upper limit of normal for age or 2-fold increase in baseline creatinine
Hepatic • Total bilirubin≥ 4 mg/dL (not applicable for newborn)
OR
ALT 2 times upper limit of normal age
This table shows the diagnostic criteria for cardiovascular, respiratory, neurologic, hematologic, renal, and hepatic dysfunction according to the International
pediatric sepsis consensus conference [16]. BP denotes blood pressure, GCS Glasgow Coma Scale, ALT alanine aminotransferase.
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a protective effect for the interventional group. Thus,
in-line filtration may have a beneficial effect on the pre-
servation of respiratory, renal and hematologic organ
function in critically ill children. The incidence of other
organ dysfunction was also lower in the filter group;
however these differences did not reach statistical sig-
nificance as the 95% CI included zero. The number
of patients suffering from neurologic dysfunction was
too small in both groups to allow any reliable statis-
tical conclusion.
This current data support previous pathophysiologi-
cal findings and confirm clinical and experimental data
[5-8,10,12-15,19]. A reduced occurrence of respiratory
dysfunction was evident for the filter group. These resultsare in accordance with our previous findings, which
revealed a statistical trend towards a decrease in the
incidence of ARDS for the filter group [15]. As a conse-
quence, the duration of mechanical ventilation in patients
receiving in-line filtration was shortened [15]. Since lung
capillaries are the first anatomical filter for infused parti-
cles, the pulmonary vessels may be the primary cause for
respiratory dysfunction as migration of particles to the
lung induces mechanical embolisation of lung capillaries
[7,19-22]. In adults suffering from ARDS, Walpot et al.
demonstrated particulate-induced formation of occlusive
microthrombi and generation of granulomas and foreign
body giant cells on autopsy [19]. Particles may harm the
pulmonary endothelium either directly or by activa-
tion of complement, platelets and/or neutrophils [7,19].
Table 2 Baseline characteristics of patients
CHARACTERISTICS CONTROL GROUP (n = 406) FILTER GROUP (n = 401) P VALUE
Age - years 5.58 ± 5.59 6.07 ± 6.01 0.23
Weight − kg 21.8 ± 20.1 23.0 ± 20.7 0.43
Paediatric Index of Mortality II (PIM II) 4.15 ± 8.76 3.42 ± 9.14 0.25
Sex − no.
Male 230 234 0.72
Female 175 168
DISEASE CATEGORY ON ADMISSION
Cardiology 150 155 0.66
Cardiac bypass 101 102 0.87
non-bypass 49 53 0.67
Hematology/Oncology 24 21 0.76
Nephrology 18 26 0.21
Gastroenterolgy 37 37 1.00
Pulmonology 21 18 0.74
Pediatric surgery 59 48 0.30
Traumatolgy 34 43 0.28
Neurosurgery 26 22 0.66
Others 37 31 0.53
This table displays the distribution of subjects between the control and filter groups by demographic characteristics, PIM II and disease categories on admission.
None of the differences between the two groups were significant. Plus-minus values are means ± SD. PIM II denotes Pediatric Index of Mortality II. P values were
calculated using the t-test for equality of means, Pearson’s Chi-Square test or Fisher’s exact test, as appropriate.
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tially generate or at least aggravate ARDS and respiratory
insufficiency.
However, the harmful effects of particles do not seem
to be restricted to the lung as primary anatomical filter.
Several authors have shown that inhaled [23,24] and in-
travenously injected [25] particles are translocated from
the lung to the systemic circulation and various extra-
pulmonary organs, either as free particles or incorpo-
rated into macrophages. These particles can be detected
in the blood, liver, kidney and the spleen. Also, particu-
late contaminants from drug preparations have been
found, after intravenous injection traversing or bypassing
the lung, in arterioles and capillaries of a striated muscle
in a hamster skinfold chamber model [6,10]. After short
ischemia-reperfusion injury, these particles damaged
the microcirculation and induced a reduction of
capillary density [6,10]. In critically ill patients with
already compromised microcirculation, further impair-
ment by particles may have additional deleterious effects
on organ function [26]. Especially the renal function is
highly dependent on vascular integrity. In critically ill
patients, acute renal failure or dysfunction is a common
problem in the course of sepsis, severe trauma, surgery,
or shock, and is an independent risk factor for mor-
bidity and mortality [27]. Renal dysfunction is mainly
caused by insufficient tissue perfusion resulting in anischemia–reperfusion injury with consecutive tubular in-
jury or necrosis [27]. However, recently a new concept
regarding the pathogenesis of acute renal failure has been
evolved [28]. In sepsis-induced acute renal failure the
renal blood flow is preserved and an increased renal vas-
cular resistance as the pathogenetic factor leads to the de-
velopment of acute renal failure or dysfunction [28]. This
increased renal vascular resistance is mainly caused by an
impairment of the microcirculation in the renal cortex
and medulla. There, sepsis induces endothelial alterations
with an adhesion of leukocytes and platelets, and a con-
secutive formation of microthromboses [28]. In the pres-
ence of such disturbed vascular integrity, particles may
either trigger or augment alterations in the renal microcir-
culation. As shown in our study, patients provided with
particle-retentive in-line filters had a lower incidence of
renal dysfunction.
The incidence of hematological dysfunction (defined
as thrombocytopenia below <80.000/mm3, decline in pla-
telet count by more than 50% or international normalized
ratio (INR) >2 [16]) was significantly decreased in the filter
group. Clinically, thrombocytopenia alone or a drop in
platelet count of >50% is associated with a raised mortality
on intensive care unit [29]. The coagulation system — as
in most critically ill patients [30] — seems to be more ac-
tivated in patients of the control group compared to
patients of the filter group. Particles obstructing small
Figure 1 Incidence of organ dysfunction in control (blue columns) and filter group (grey columns) (A) and corresponding differences
in incidence rates with 95% confidence intervals (B). Respiratory, renal and hematologic dysfunction were significantly reduced in the filter
group (Panel A). Filled rhombi: differences in incidence rates; horizontal lines: 95% confidence intervals. (Panel B).
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tion of clotting factors either directly or via interference
with the endothelium with subsequent activation of com-
plement, platelets and/or neutrophils [7,19]. This has been
well illustrated for the lung as particles in capillaries as
well as in the interstitium were surrounded by an accumu-
lation of platelets and fibrin deposits [7,19]. In addition,
also a systemic hypercoagulability, as proven for inhaledTable 3 Organ dysfunction







Table shows the incidence of the different organ dysfunctions and the resulting dif
according to the Wald method.particles [31,32], can be hypothesized for intravenously
injected particles after distribution to several organs.
Thrombogenic effects in the microcirculation induce
and modulate an inflammatory activity [30]. Vice-versa,
systemic inflammation results in activation of the coagu-
lation [30]. Additionally infused particles may initiate
and aggravate the cross-talk between the inflammatory




38 −5.06 −9.52 − −0.59
24 −3.87 −7.58 − −0.15
18 −3.89 −7.26 − −0.51
54 −1.31 −6.12 − 3.49
20 −1.42 −4.61 − 1.78
3 −0.83 −0.83 − 1.34
ferences in the incidence rates and corresponding confidence intervals
Boehne et al. BMC Pediatrics 2013, 13:21 Page 7 of 8
http://www.biomedcentral.com/1471-2431/13/21circle. In our study these synergistic effects of parti-
cles on the coagulation and inflammatory pathways be-
come clinically obvious. Patients not being protected
against particle infusion suffer from a higher incidence of
SIRS [15] and haematological dysfunction. Additionally, as
shown for septic patients the mutual activation of inflam-
mation and coagulation results in an considerable increase
of organ failure or dysfunction at multiple sites [33]. This
resembles another potential pathophysiological explan-
ation for the higher incidence of organ dysfunction in the
control group.
In the control as well as in the filter group we used a
standardized infusion regimen for all patients. In both
groups medications were prepared according to the ma-
nufacturer’s instructions and parenteral nutrition and
certain drugs were supplied by a centralized intravenous
additive service to guarantee chemical stability and aseptic
standards. The infusion therapy was further optimized by
the use of a computer program to prevent formation of
particles by precipitations and incompatibilities. It is re-
markable, that although we used the best of practice for
the infusion management in both groups, the additional
use of in-line filtration resulted in a further positive effect
for patients.
However, there is one inherent limitation of this study.
Although, data for organ dysfunction was recorded pro-
spectively, size and power of the study had not been cal-
culated for the detection of a single reduction in organ
dysfunction beforehand. Therefore, use of a contingency
table and subsequent assessment of the significance by
Pearson’s Chi-Square test or Fisher’s exact test with the
computation of a P value would have been statistically
incorrect. All data is therefore based on a descriptive
statistical analysis. The presented results are related to
the significant differences in the incidence rates and its
95% CI and have to be interpreted on the basis of the
underlying descriptive statistic.Conclusion
In conclusion, our investigation demonstrated potential
beneficial effects of in-line filtration on the preservation
of various organ systems. The clinical data further sup-
port our hypothesis that infused particles act directly on
the microcirculation of several organ systems such as
the kidney and lung and induce a systemic hypercoagul-
ability and inflammation. Further experimental and clin-
ical investigations are necessary to clarify the exact impact
as well as the underlying mechanisms of infused particles
in order to identify their exact role in the development of
complications in critically ill patients.
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